AllianceBernstein’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $385K | Hold |
238,930
| – | – | ﹤0.01% | 2769 |
|
|
2025
Q4 | $385K | Hold |
238,930
| – | – | ﹤0.01% | 2788 |
|
|
2025
Q3 | $652K | Hold |
238,930
| – | – | ﹤0.01% | 2543 |
|
|
2025
Q2 | $870K | Buy |
238,930
+186,660
| +357% | +$513K | ﹤0.01% | 2367 |
|
|
2025
Q1 | $100K | Sell |
52,270
-25,370
| -33% | -$51.8K | ﹤0.01% | 3068 |
|
|
2024
Q4 | $148K | Hold |
77,640
| – | – | ﹤0.01% | 3076 |
|
|
2024
Q3 | $102K | Hold |
77,640
| – | – | ﹤0.01% | 3130 |
|
|
2024
Q2 | $79.2K | Buy |
+77,640
| New | +$95.9K | ﹤0.01% | 3146 |
|
|
2022
Q2 | – | Sell |
-150,335
| Closed | -$108K | – | 3259 |
|
|
2022
Q1 | $108K | Buy |
150,335
+700
| +0.5% | +$1.5K | ﹤0.01% | 3107 |
|
|
2021
Q4 | $338K | Hold |
149,635
| – | – | ﹤0.01% | 2908 |
|
|
2021
Q3 | $431K | Hold |
149,635
| – | – | ﹤0.01% | 2810 |
|
|
2021
Q2 | $567K | Buy |
149,635
+82,800
| +124% | +$279K | ﹤0.01% | 2760 |
|
|
2021
Q1 | $226K | Hold |
66,835
| – | – | ﹤0.01% | 3015 |
|
|
2020
Q4 | $187K | Sell |
66,835
-107,171
| -62% | -$313K | ﹤0.01% | 3007 |
|
|
2020
Q3 | $437K | Sell |
174,006
-4,300
| -2% | -$37.7K | ﹤0.01% | 2590 |
|
|
2020
Q2 | $2.42M | Buy |
178,306
+55,487
| +45% | +$574K | ﹤0.01% | 1742 |
|
|
2020
Q1 | $931K | Hold |
122,819
| – | – | ﹤0.01% | 2065 |
|
|
2019
Q4 | $776K | Hold |
122,819
| – | – | ﹤0.01% | 2379 |
|
|
2019
Q3 | $481K | Hold |
122,819
| – | – | ﹤0.01% | 2569 |
|
|
2019
Q2 | $594K | Buy |
122,819
+9,000
| +8% | +$51.2K | ﹤0.01% | 2530 |
|
|
2019
Q1 | $932K | Buy |
113,819
+4,399
| +4% | +$30.2K | ﹤0.01% | 2265 |
|
|
2018
Q4 | $605K | Buy |
109,420
+57,620
| +111% | +$451K | ﹤0.01% | 2397 |
|
|
2018
Q3 | $457K | Hold |
51,800
| – | – | ﹤0.01% | 2662 |
|
|
2018
Q2 | $517K | Buy |
51,800
+8,600
| +20% | +$86.1K | ﹤0.01% | 2598 |
|
|
2018
Q1 | $412K | Hold |
43,200
| – | – | ﹤0.01% | 2577 |
|
|
2017
Q4 | $642K | Hold |
43,200
| – | – | ﹤0.01% | 2463 |
|
|
2017
Q3 | $850K | Hold |
43,200
| – | – | ﹤0.01% | 2357 |
|
|
2017
Q2 | $621K | Buy |
43,200
+26,400
| +157% | +$335K | ﹤0.01% | 2528 |
|
|
2017
Q1 | $155K | Hold |
16,800
| – | – | ﹤0.01% | 2894 |
|
|
2016
Q4 | $175K | Buy |
16,800
+1,600
| +11% | +$13.8K | ﹤0.01% | 2918 |
|
|
2016
Q3 | $138K | Buy |
15,200
+1,100
| +8% | +$9.35K | ﹤0.01% | 2905 |
|
|
2016
Q2 | $105K | Buy |
+14,100
| New | +$123K | ﹤0.01% | 2904 |
|
|
2015
Q2 | – | Sell |
-2,300
| Closed | -$26K | – | 3003 |
|
|
2015
Q1 | $26K | Hold |
2,300
| – | – | ﹤0.01% | 3225 |
|
|
2014
Q4 | $27K | Sell |
2,300
-1,300
| -36% | -$18.6K | ﹤0.01% | 3187 |
|
|
2014
Q3 | $80K | Hold |
3,600
| – | – | ﹤0.01% | 3007 |
|
|
2014
Q2 | $100K | Buy |
+3,600
| New | +$86.7K | ﹤0.01% | 2995 |
|
Other funds holding AKBA
VCM
VPM
AllianceBernstein's AKBA Position: Q1 2026 in Review
AllianceBernstein held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 238,930 shares worth $385K. The position accounts for ﹤0.01% of the portfolio, ranked #2769.
AllianceBernstein first reported a position in AKBA in Q2 2014 and has held it in 36 quarters since. The position peaked at $2.42M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- AllianceBernstein held 238,930 shares of Akebia Therapeutics worth $385K as of Q1 2026.
- AllianceBernstein left its Akebia Therapeutics share count unchanged in Q1 2026.
- Akebia Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2769 holding.
- AllianceBernstein first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 36 quarters since.
- AllianceBernstein's Akebia Therapeutics position peaked at $2.42M in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.